Prioritizing cancer-related key miRNA-target interactions by integrative genomics

Yun Xiao1, Jinxia Guan, Yanyan Ping

  • 1College of Bioinformatics Science and Technology, Department of Neurology, The Affiliated Hospital and Harbin Medical University, Harbin, Heilongjiang 150086, China.

Insights

This study introduces PCmtI, a bioinformatics tool to identify crucial microRNA-target interactions in cancer. PCmtI prioritizes these interactions by analyzing sequence, expression, and function, aiding in cancer research and discovery.

Area of Science:

  • Genomics
  • Bioinformatics
  • Molecular Biology

Background:

  • MicroRNAs (miRNAs) are key regulators in cancer, acting as oncogenes or tumor suppressors.
  • Identifying specific miRNA-target interactions crucial for cancer pathogenesis is a significant challenge.

Purpose of the Study:

  • To develop and validate a bioinformatics approach (PCmtI) for prioritizing cancer-related miRNA-target interactions.
  • To enhance the discovery of novel interactions involved in cancer development.

Main Methods:

  • Systematic analysis of manually curated miRNA-target interactions from literature.
  • Integration of sequence, expression, and functional features of known interactions.
  • Development and cross-validation of the PCmtI bioinformatics approach.

Main Results:

  • Cancer-related interactions exhibit distinct features like more miRNA binding sites and stronger expression associations compared to non-disease interactions.
  • PCmtI achieved high accuracy (93.9% AUC) in prioritizing interactions via ten-fold cross-validation.
  • Case studies, including miR-155, demonstrated PCmtI's ability to identify functionally relevant interactions.

Conclusions:

  • The PCmtI approach effectively prioritizes cancer-related miRNA-target interactions.
  • This method offers a valuable tool for discovering novel interactions in cancer research.
  • PCmtI aids in understanding the role of miRNAs in cancer pathogenesis.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...